SUPN Supernus, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1625297 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY16.3%
TTM net income YoY251.6%
TTM EPS YoY253.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin85.0%
Operating margin40.6%
Net margin32.8%
FCF margin2.3%
EBITDA margin41.1%
Returns
ROE—
ROA32.8%
ROIC (approx.)—
Asset turnover1.00x
Leverage & solvency
Liabilities / assets104.5%
Debt / equity—
Current ratio0.61x
Interest coverage32.82x
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio25.8%
Payout ratio—
Capex / revenue4.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $356.00M | $343.00M | $317.00M | $358.00M | $314.00M | $302.00M | $266.00M | $299.00M |
| Cost of revenue | $51.00M | $50.00M | $40.00M | $67.00M | $83.00M | $52.00M | $44.00M | $48.00M |
| Gross profit | $305.00M | $294.00M | $277.00M | $292.00M | $230.00M | $250.00M | $221.00M | $250.00M |
| R&D expense | $5.00M | $12.00M | $16.00M | $21.00M | $33.00M | $21.00M | $22.00M | $31.00M |
| SG&A expense | $119.00M | $122.00M | $124.00M | $189.00M | $154.00M | $158.00M | $133.00M | $175.00M |
| Operating income | $180.00M | $160.00M | $137.00M | $81.00M | $43.00M | $72.00M | $66.00M | $46.00M |
| Interest expense | $2.00M | $2.00M | $7.00M | $6.00M | $12.00M | $15.00M | $12.00M | $13.00M |
| Pretax income | $182.00M | $160.00M | $115.00M | $81.00M | $37.00M | $62.00M | $59.00M | $38.00M |
| Income tax | $45.00M | $38.00M | $26.00M | -$21.00M | -$5.00M | $44.00M | $11.00M | $17.00M |
| Net income | $137.00M | $122.00M | $89.00M | $102.00M | $42.00M | $18.00M | $47.00M | $21.00M |
| EBITDA | $181.00M | $162.00M | $139.00M | $83.00M | $46.00M | $72.00M | $69.00M | $64.00M |
| EPS (basic) | 1.16 | 1.02 | 0.71 | — | 0.34 | 0.15 | 0.38 | — |
| EPS (diluted) | 1.12 | 0.98 | 0.69 | — | 0.33 | 0.14 | 0.38 | — |
| Weighted avg. shares (diluted) | 122.00M | 124.00M | 129.00M | — | 129.00M | 126.00M | 125.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $305.00M | $222.00M | $175.00M | $195.00M | $445.00M | $510.00M | $372.00M | $319.00M |
| Short-term investments | — | — | — | $0 | $0 | $0 | $1.00M | $1.00M |
| Receivables | $273.00M | $271.00M | $273.00M | $253.00M | $259.00M | $240.00M | $243.00M | $254.00M |
| Inventory | $149.00M | $150.00M | $152.00M | $153.00M | $155.00M | $149.00M | $163.00M | $167.00M |
| Current assets | $800.00M | $725.00M | $667.00M | $652.00M | $922.00M | $951.00M | $883.00M | $827.00M |
| PP&E, net | $175.00M | $162.00M | $157.00M | $144.00M | $124.00M | $117.00M | $104.00M | $100.00M |
| Goodwill | — | — | — | $2.00M | — | — | — | $2.00M |
| Total assets | $1.33B | $1.23B | $1.20B | $1.20B | $1.42B | $1.45B | $1.38B | $1.32B |
| Current liabilities | $1.30B | $868.00M | $779.00M | $914.00M | $965.00M | $1.06B | $1.00B | $924.00M |
| Short-term debt | $488.00M | $0 | $0 | $29.00M | $18.00M | $18.00M | $18.00M | $18.00M |
| Long-term debt | $0 | $487.00M | $486.00M | $290.00M | $304.00M | $308.00M | $311.00M | $315.00M |
| Total debt | $488.00M | $487.00M | $486.00M | $319.00M | $322.00M | $326.00M | $329.00M | $333.00M |
| Total liabilities | $1.39B | $1.44B | $1.34B | $1.30B | $1.62B | $1.71B | $1.66B | $1.65B |
| Shareholders' equity | -$60.00M | -$208.00M | -$144.00M | -$98.00M | -$207.00M | -$257.00M | -$285.00M | -$337.00M |
| Net debt | $183.00M | $265.00M | $311.00M | $124.00M | -$123.00M | -$184.00M | -$43.00M | $14.00M |
| Cash flow statement | ||||||||
| Operating cash flow | $97.00M | $229.00M | -$9.00M | -$221.00M | -$39.00M | $158.00M | $75.00M | -$17.00M |
| Capital expenditure | $14.00M | $7.00M | $20.00M | $24.00M | $20.00M | $17.00M | $5.00M | $16.00M |
| Free cash flow | $83.00M | $222.00M | -$29.00M | -$245.00M | -$59.00M | $141.00M | $70.00M | -$33.00M |
| Investing cash flow | -$14.00M | -$8.00M | -$19.00M | -$24.00M | -$20.00M | -$17.00M | -$5.00M | $8.00M |
| Financing cash flow | $0 | -$173.00M | $7.00M | -$5.00M | -$3.00M | -$5.00M | -$17.00M | $40.00M |
| Depreciation & amortization | $1.00M | $2.00M | $2.00M | $2.00M | $3.00M | $0 | $3.00M | $18.00M |
| Stock-based compensation | $8.00M | $11.00M | $9.00M | $5.00M | $6.00M | $8.00M | $6.00M | $6.00M |
| Share buybacks | $0 | $176.00M | $125.00M | $0 | $0 | $0 | $11.00M | $50.00M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.